A

Ark Clinical Research | Long Beach, CA

Research site
(Unclaimed)
Location
2600 Redondo Avenue, Suite 400, Long Beach, California, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

18 of 38
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal in...

Active, not recruiting
Respiratory Syncytial Virus
Biological: mRNA-1273.214
Biological: mRNA-1345

The purpose of the study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1345 in children aged 2 to <5 years of age and in chil...

Active, not recruiting
Respiratory Syncytial Virus
Biological: mRNA-1345
Biological: Placebo

The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in p...

Enrolling
Type 2 Diabetes
Drug: Dapagliflozin
Drug: Orforglipron

The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes a...

Enrolling
Type 2 Diabetes
Drug: Orforglipron
Drug: Placebo

This study is designed to evaluate the safety and immunogenicity of two monovalent Norovirus (NoV) oral tableted vaccine candidates, VXA-G1.1-NN and...

Active, not recruiting
Norovirus Infections
Drug: Placebo
Drug: Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Enrolling
COVID-19
Influenza
Biological: Placebo
Biological: Influenza and COVID-19 Combination B

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and ina...

Begins enrollment this month
Diabetes Type 2
Drug: Placebo
Drug: Retatrutide

The purpose of this study is to evaluate the safety and efficacy of EB01 Cream (0.2%, 1.0%, 2.0%) applied twice per day (BID) for the treatment of mo...

Active, not recruiting
Allergic Contact Dermatitis
Drug: EB01 Cream 2.0%
Drug: EB01 Cream Placebo

The primary objective of this study is to evaluate the safety and tolerability of intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID...

Enrolling
COVID-19
SARS-CoV2 Infection
Drug: Placebo
Drug: IMM-BCP-01

A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokine...

Enrolling
Type 2 Diabetes Mellitus
Drug: BMF-219

The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to p...

Active, not recruiting
Overactive Bladder Syndrome
Drug: Placebo
Drug: V117957

This is a Phase 2/3 randomized, observer-blinded, placebo-controlled, age de-escalation trial to evaluate the safety and immunogenicity of 2 primary...

Active, not recruiting
COVID-19
Other: Placebo
Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Open Label Crossover Vaccination period)

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Active, not recruiting
Lower Respiratory Tract Illness
Biological: Placebo
Biological: RSVpreF

The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 t...

Active, not recruiting
Norovirus Acute Gastroenteritis
Biological: mRNA-1403
Biological: Placebo

The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.

Enrolling
Atopic Dermatitis
Drug: ruxolitinib cream

Trial conditions

COVID-19 (12 trials)
Diabetes Mellitus (5 trials)
Human Influenza (5 trials)
Type 2 Diabetes Mellitus (5 trials)
Dermatitis (4 trials)
Atopic Dermatitis (3 trials)
Eczema (3 trials)
Cardiovascular Diseases (2 trials)
Virus Diseases (2 trials)
Allergic Contact Dermati... (1 trial)

And 21 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems